Mersana Therapeutics to Present at Jefferies Virtual Global Healthcare Conference
May 28, 2020 17:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Proposed Public Offering of Common Stock
May 28, 2020 06:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study
May 27, 2020 06:00 ET
|
Mersana Therapeutics, Inc.
- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer - Data continue to support a NaPi2b...
Mersana Therapeutics to Present Two Posters at the American Association for Cancer Research 2020 Virtual Annual Meeting
May 15, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation Study
May 14, 2020 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the American Society of Clinical Oncology 2020 Virtual Scientific Program
May 13, 2020 17:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Report Interim Data from Phase 1 Dose Expansion of XMT-1536
May 13, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update
May 08, 2020 06:00 ET
|
Mersana Therapeutics, Inc.
Recently presented promising XMT-1536 Phase 1 dose escalation data and established maximum tolerated dose, subsequently raising $65M of gross proceeds from the Company’s ATM facility Company to...
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2020 Financial Results and Business Updates
April 29, 2020 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Appointment of Martin H. Huber, M.D., to Board of Directors
April 15, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...